Navigation Links
Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs

CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc. ( announced today that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer's disease, depression and ischemia. Neuronascent has received grants and funding from Maryland Department of Business and Economic Development Challenge Investment Program; Maryland Industrial Partnerships in collaboration with University of Maryland, Baltimore; and Jefferson Corner Group I, LLC, a member-managed angel fund located in Charlottesville, Virginia designed to capitalize on the growth in entrepreneurial activity in Charlottesville and other areas. This is the Company's second award from the Challenge Investment Program.

The company's lead compounds, currently in preclinical testing, aim to replace damaged neurons, restore neurons critical to cognition and memory and enhance neuroprotection against neurodegenerative diseases. Results from recent animal studies show a reversal of cognitive loss in aged mice to young levels.

"Our lead compound for Alzheimer's disease may represent the first disease-modifying therapeutic under development," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer. Dr. Kelleher-Andersson went on to say, "This funding affords us the opportunity to pursue multiple preclinical studies to further develop our lead agents for clinical trials."

Founded in 2004 by Dr. Kelleher-Andersson, Neuronascent, Inc. is a small-molecule central nervous system drug discovery company developing novel therapeutics based on the science of neurogenesis that target Alzheimer's disease, depression and ischemia. Neuronascent has laboratories in Rockville and Walkersville, Maryland.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.

SOURCE Neuronascent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
3. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
4. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
5. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Theranostics Health Receives Green Light to Perform Clinical Testing
8. StemCor Systems Receives CE Mark for MarrowMiner(TM) System for Bone Marrow Collection
9. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Unique Hearing Aid Receives Patent Protection
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
Breaking Medicine News(10 mins):